OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Advance purchase agreement is for up to 200 million doses of Nuvaxovid
Biotech company Novavax announced that the first doses of its Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) have begun shipping to EU member states. Nuvaxovid, also known as NVX-CoV2373, is the first protein-based COVID-19 vaccine authorized for use in Europe.
In August 2021, Novavax and the European Commission (EC) signed an advance purchase agreement for up to 100 million doses of Nuvaxovid, with the option for an additional 100 million doses. The doses will be shipping from Novavax' Netherlands distribution center starting this week. The first wave of shipments features several countries, such as Austria, France and Germany.
"... The Novavax COVID-19 vaccine provides a differentiated option to bolster vaccination rates across Europe," says Stanley C. Erck, Novavax’s president and CEO. "Nuvaxovid has demonstrated efficacy, a reassuring safety and tolerability profile, and is built on a well-understood protein-based vaccine platform used for other vaccines for decades."
The EC granted Nuxavoid conditional marketing authorization for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Novavax expects to submit its regulatory filing for a pediatric indication in adolescents 12 to 17 years of age to global regulatory authorities, including the European Medicines Agency, during Q1 of 2022. The vaccine is yet to be authorized for use by the FDA.